Biomarin Pharmaceutical
- Country
- π¨π¦Canada
- Ownership
- -
- Established
- 1997-01-01
- Employees
- -
- Market Cap
- $17.2B
- Website
- http://www.biomarin.com
Study of BMN 349 Single Dose in (PiZZ) and (PiMZ) Adult Participants
- First Posted Date
- 2024-12-17
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 12
- Registration Number
- NCT06738017
- Locations
- πΊπΈ
University of California, San Diego, San Diego, California, United States
A Phase 2 Basket Study of Vosoritide in Children with Turner Syndrome, SHOX Deficiency and Noonan Syndrome with an Inadequate Response to Human Growth Hormone
- Conditions
- Interventions
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 72
- Registration Number
- NCT06668805
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 80
- Registration Number
- NCT06455059
- Locations
- πΊπΈ
Children's National Medical Center, Washington, District of Columbia, United States
π¦πΊMurdoch Children's Research Institute, Parkville, Victoria, Australia
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
- Conditions
- Interventions
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 100
- Registration Number
- NCT06382155
- Locations
- πΊπΈ
Centricity Research, Columbus, Georgia, United States
πΊπΈSt. Luke's Children's Endocrinology, Boise, Idaho, United States
A Study to Assess Growth in Children with Idiopathic Short Stature
- Conditions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 600
- Registration Number
- NCT06309979
- Locations
- πΊπΈ
Harbor-UCLA Medical Center - The Lundquist Institute (Los Angeles Biomedical Research Institute (LA BioMed), Los Angeles, California, United States
πΊπΈCentricity Research, Columbus, Georgia, United States
πΊπΈRocky Mountain Clinical Research - Idaho Falls, Idaho Falls, Idaho, United States
A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)
- Conditions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 200
- Registration Number
- NCT06305234
- Locations
- πΊπΈ
UT Southwestern Medical Center, Dallas, Texas, United States
πΊπΈNorthwestern University, Chicago, Illinois, United States
πΊπΈUniversity of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants with Duchenne Muscular Dystrophy
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 18
- Registration Number
- NCT06280209
- Locations
- π³π±
Leids Universitair Medisch Centrum, Leiden, Netherlands
πΉπ·Yeditepe University Kosuyolu Hospital, Istanbul, Turkey
π¬π§Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom
Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A
- Conditions
- Interventions
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 6
- Registration Number
- NCT06224907
- Locations
- π―π΅
Asahikawa Medical University Hospital, Hokkaido, Asahikawa, Japan
π―π΅Nagoya University Hospital, Aichi, Nagoya, Japan
π―π΅Tokyo Medical University Hospital, Tokyo, Shinjuku-ku, Japan
A Multicenter Multinational Observational Study of Children With Hypochondroplasia
- Conditions
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 400
- Registration Number
- NCT06212947
- Locations
- πͺπΈ
Hospital Universitario La Paz, Madrid, Spain
πͺπΈVithas Hospital San Jose, Vitoria, Spain
πΊπΈPhoenix Children's Hospital, Phoenix, Arizona, United States
A Participant-mediated Observational Virtual Registry of Children With Achondroplasia in the United States
- Conditions
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 300
- Registration Number
- NCT06168201
- Locations
- πΊπΈ
PicnicHealth, San Francisco, California, United States